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0In 2004, a 68-year-old man received aortocoronary
bypass surgery and a 23-mm Hancock porcine
bioprosthesis (Medtronic, Minneapolis, Minne-
sota). Six years later, in January 2011, cardiac
re-evaluation was performed due to progressive
dyspnea. Invasive angiography showed open bypass
grafts and severe stenosis of the porcine aortic
bioprosthesis. Due to significant comorbidities, a
23-mm Sapien XT (Edwards Lifesciences, Irvine,
California) transcatheter aortic valve (TAVI) was
implanted as valve-in-valve. The procedure was
uneventful. Initial angiography and echocardiogra-
phy showed a good function of the valve with no
insufficiency and a mean gradient of 20 mm Hg
(Online Video 1).
In March 2011, 3 months after the procedure,
the patient was readmitted with cardiac decom-
pensation. Reangiography showed open bypass
grafts, but an invasive gradient of 50 mm Hg
over the Sapien valve. Echocardiography con-
firmed the severe stenosis of the Sapien valve
with a maximum gradient of 66 mm Hg, a mean
of 43 mm Hg, and a valve opening area of 0.6
cm2. Due to the severe dyspnea, reoperation was
cheduled after recompensation. In May 2011,
oth the Sapien valve and the 2004 implanted
ancock bioprosthesis was explanted (Fig. 1)
nd replaced with a 21-mm Trifecta (St. Jude
edical, Inc., St. Paul, Minnesota) bioprosthe-
is. The post-operative course was uneventful.
Post-explantation assessment of the valves
howed the implanted 23-mm Sapien valve in-
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3-mm Hancock bioprosthesis. This leads to
symmetrical commissural distances and wrin-
les of the leaflets (Fig. 2). In vitro investigation
f the valves under pulsatile conditions showed
olding and uneven leaflet coaptation in the
iastolic state and a severely limited opening of
he valve in systole, with a visual orifice area of
.54 cm2 (Online Video 2). Pressure gradients
were 24.2 mm Hg (mean) and 42.2 mm Hg (maxi-
mum) at a cardiac output of 4.3 l/min.
Even though TAVI shows promising results
in high-risk patients (1), the concept of valve-
in-valve in degenerated aortic bioprostheses is
quite new (2). Reports successfully demonstrated
the feasibility of this approach (3). However,
experimental studies could show the rigidity of
Figure 1. The Explanted 23-mm Hancock Bioprosthesis With
the Implanted 23-mm Sapien Transcatheter Valve
The arrowheads show the uneven commissures in the Hancock
valve (see Online Video 1).the bioprosthesis can constrain the TAVI valve
(A) diastole; (B) systole (see Online Video 2).
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592and prevent full expansion of the stents (4). Because the
inner diameter of a 23-mm Hancock bioprosthesis is only
19-mm, a circumferential part of 12.5-mm is missing to
unfold the 23-mm Edwards Sapien transcatheter valve.
This leads to uneven commissural distances that might
affect leaflet coaptation and leaflet folding, which could
severely restrict the opening of the valve. Our case
emphasizes the difficulties of valve-in-valve TAVI for
degenerated aortic bioprosthesis. These procedures
should be done with caution.
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APPENDIXFigure 2. In Vitro Assessment in Diastole and SystoleFor accompanying videos, please see the online version of this article.
